Symbols / DRTS Stock $8.08 +2.28% Alpha Tau Medical Ltd.
DRTS (Stock) Chart
About
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Stock Fundamentals
Scroll to Statements| Market Cap | 711.12M | Enterprise Value | 651.72M | Income | -42.63M | Sales | — | Book/sh | 0.88 | Cash/sh | 0.83 |
| Dividend Yield | — | Payout | 0.00% | Employees | 121 | IPO | — | P/E | — | Forward P/E | -18.98 |
| PEG | — | P/S | — | P/B | 9.22 | P/C | — | EV/EBITDA | -15.87 | EV/Sales | — |
| Quick Ratio | 6.99 | Current Ratio | 7.45 | Debt/Eq | 17.80 | LT Debt/Eq | — | EPS (ttm) | -0.53 | EPS next Y | -0.43 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-18 | ROA | -27.55% | ROE | -61.00% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 88.01M | Shs Float | 45.32M | Short Float | 1.10% |
| Short Ratio | 3.13 | Short Interest | — | 52W High | 8.60 | 52W Low | 2.50 | Beta | 1.05 | Avg Volume | 284.54K |
| Volume | 141.60K | Target Price | $9.50 | Recom | None | Prev Close | $7.90 | Price | $8.08 | Change | 2.28% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.50
Mean price target
2. Current target
$8.08
Latest analyst target
3. DCF / Fair value
$-4.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.08
Low
$5.00
High
$12.00
Mean
$9.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Citigroup | Buy → Buy | $9 |
| 2026-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2026-03-04 | down | Piper Sandler | Overweight → Neutral | $5 |
| 2026-02-24 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-12-10 | main | Citigroup | Buy → Buy | $7 |
| 2025-11-24 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-10-22 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-04-29 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-11-22 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-23 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-11 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-20 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-15 | reit | Piper Sandler | Overweight → Overweight | $7 |
| 2024-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-03-08 | reit | Piper Sandler | Overweight → Overweight | $7 |
- Is Alpha Tau (DRTS) stock trading at a discount | Q4 2025: Profit Exceeds Views - Popular Market Picks - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 02
- Alpha Tau Medical: 2026 Is The Breakthrough Year - Seeking Alpha ue, 24 Mar 2026 07
- Is Alpha Tau (DRTS) stock trading at a discount | Q4 2025: Profit Exceeds Views - Debt Refinancing - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 22
- Cancer therapy Alpha DaRT advances in 5 U.S. trials with 2026 results ahead - Stock Titan hu, 29 Jan 2026 08
- Alpha Tau Medical Ltd. (DRTS) Stock Analysis: Promising Potential With A 28.21% Upside - DirectorsTalk Interviews hu, 05 Mar 2026 08
- Piper Sandler cuts Alpha Tau Medical stock rating on valuation - Investing.com Wed, 04 Mar 2026 08
- New Analyst Forecast: $DRTS Given $7 Price Target | DRTS Stock News - Quiver Quantitative Wed, 10 Dec 2025 08
- Alpha Tau Medical (NASDAQ: DRTS) CEO details equity holdings - Stock Titan Wed, 18 Mar 2026 07
- DRTS (Alpha Tau Medical Ltd. Ordinary Shares) posts narrower Q4 2025 loss than estimates, shares rise 0.75 percent today. - GDR - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 20
- Alpha Tau Medical Ltd. (DRTS) Stock Analysis: Promising 114% Potential Upside In Biotechnology - DirectorsTalk Interviews hu, 13 Nov 2025 08
- Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026 - Seeking Alpha Fri, 23 Jan 2026 08
- Japan okays first-in-kind Alpha DaRT for hard-to-treat head and neck cancer - Stock Titan ue, 24 Feb 2026 08
- DRTS SEC Filings - Alpha Tau Medical Ltd 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 07
- Pancreatic cancer trial data from Jerusalem lands DDW podium slot - Stock Titan ue, 31 Mar 2026 07
- Alpha Tau (DRTS) director discloses initial shares, RSUs and options - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
42.29
+17.33%
|
36.04
+1.01%
|
35.68
+11.03%
|
32.14
|
| Research And Development |
|
32.06
+18.67%
|
27.02
+2.26%
|
26.42
+26.49%
|
20.89
|
| Selling General And Administration |
|
10.22
+13.31%
|
9.02
-2.53%
|
9.26
-17.70%
|
11.25
|
| Selling And Marketing Expense |
|
1.86
-20.82%
|
2.35
+22.09%
|
1.92
+97.54%
|
0.97
|
| General And Administrative Expense |
|
8.36
+25.33%
|
6.67
-8.99%
|
7.33
-28.62%
|
10.27
|
| Other Gand A |
|
8.36
+25.33%
|
6.67
-8.99%
|
7.33
-28.62%
|
10.27
|
| Total Expenses |
|
42.29
+17.33%
|
36.04
+1.01%
|
35.68
+11.03%
|
32.14
|
| Operating Income |
|
-42.29
-17.33%
|
-36.04
-1.01%
|
-35.68
-11.03%
|
-32.14
|
| Total Operating Income As Reported |
|
-42.29
-17.33%
|
-36.04
-1.01%
|
-35.68
-11.03%
|
-32.14
|
| EBITDA |
|
-40.93
-34.90%
|
-30.34
-8.38%
|
-27.99
+14.56%
|
-32.76
|
| Normalized EBITDA |
|
-37.29
-21.45%
|
-30.70
-2.98%
|
-29.82
-1.45%
|
-29.39
|
| Reconciled Depreciation |
|
1.23
+11.80%
|
1.10
+2.61%
|
1.07
+9.70%
|
0.98
|
| EBIT |
|
-42.16
-34.09%
|
-31.44
-8.17%
|
-29.07
+13.86%
|
-33.74
|
| Total Unusual Items |
|
-3.64
-1096.16%
|
0.36
-79.98%
|
1.82
+154.01%
|
-3.38
|
| Total Unusual Items Excluding Goodwill |
|
-3.64
-1096.16%
|
0.36
-79.98%
|
1.82
+154.01%
|
-3.38
|
| Net Income |
|
-42.63
-34.26%
|
-31.75
-8.89%
|
-29.16
+13.64%
|
-33.76
|
| Pretax Income |
|
-42.51
-33.90%
|
-31.74
-8.93%
|
-29.14
+13.64%
|
-33.74
|
| Net Non Operating Interest Income Expense |
|
3.42
-13.09%
|
3.93
-16.60%
|
4.72
+166.59%
|
1.77
|
| Interest Expense Non Operating |
|
0.35
+14.52%
|
0.30
+304.00%
|
0.07
|
0.00
|
| Net Interest Income |
|
3.42
-13.09%
|
3.93
-16.60%
|
4.72
+166.59%
|
1.77
|
| Interest Expense |
|
0.35
+14.52%
|
0.30
+304.00%
|
0.07
|
0.00
|
| Interest Income Non Operating |
|
3.84
-10.29%
|
4.28
-11.45%
|
4.83
+169.83%
|
1.79
|
| Interest Income |
|
3.84
-10.29%
|
4.28
-11.45%
|
4.83
+169.83%
|
1.79
|
| Other Income Expense |
|
-3.64
-1096.16%
|
0.36
-79.98%
|
1.82
+154.01%
|
-3.38
|
| Gain On Sale Of Security |
|
-3.64
-1096.16%
|
0.36
-79.98%
|
1.82
+154.01%
|
-3.38
|
| Tax Provision |
|
0.12
+1916.67%
|
0.01
-62.50%
|
0.02
-20.00%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.84
-1096.16%
|
0.08
-79.98%
|
0.42
+154.01%
|
-0.78
|
| Net Income Including Noncontrolling Interests |
|
-42.63
-34.26%
|
-31.75
-8.89%
|
-29.16
+13.64%
|
-33.76
|
| Net Income From Continuing Operation Net Minority Interest |
|
-42.63
-34.26%
|
-31.75
-8.89%
|
-29.16
+13.64%
|
-33.76
|
| Net Income From Continuing And Discontinued Operation |
|
-42.63
-34.26%
|
-31.75
-8.89%
|
-29.16
+13.64%
|
-33.76
|
| Net Income Continuous Operations |
|
-42.63
-34.26%
|
-31.75
-8.89%
|
-29.16
+13.64%
|
-33.76
|
| Minority Interests |
|
—
|
—
|
—
|
—
|
| Normalized Income |
|
-39.83
-24.34%
|
-32.03
-4.81%
|
-30.56
+1.93%
|
-31.16
|
| Net Income Common Stockholders |
|
-42.63
-34.26%
|
-31.75
-8.89%
|
-29.16
+13.64%
|
-33.76
|
| Diluted EPS |
|
—
|
-0.45
-7.14%
|
-0.42
+20.75%
|
-0.53
|
| Basic EPS |
|
—
|
-0.45
-7.14%
|
-0.42
+20.75%
|
-0.53
|
| Basic Average Shares |
|
—
|
69.93
+0.79%
|
69.38
+9.20%
|
63.53
|
| Diluted Average Shares |
|
—
|
69.93
+0.79%
|
69.38
+9.20%
|
63.53
|
| Diluted NI Availto Com Stockholders |
|
-42.63
-34.26%
|
-31.75
-8.89%
|
-29.16
+13.64%
|
-33.76
|
| Total Other Finance Cost |
|
0.07
+75.61%
|
0.04
+5.13%
|
0.04
+85.71%
|
0.02
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
107.39
|
| Current Assets |
|
85.76
|
| Cash Cash Equivalents And Short Term Investments |
|
81.79
|
| Cash And Cash Equivalents |
|
12.66
|
| Other Short Term Investments |
|
69.13
|
| Receivables |
|
0.34
|
| Other Receivables |
|
0.34
|
| Prepaid Assets |
|
0.47
|
| Restricted Cash |
|
3.15
|
| Total Non Current Assets |
|
21.63
|
| Net PPE |
|
21.16
|
| Gross PPE |
|
24.13
|
| Accumulated Depreciation |
|
-2.96
|
| Properties |
|
0.00
|
| Land And Improvements |
|
5.25
|
| Machinery Furniture Equipment |
|
0.81
|
| Construction In Progress |
|
0.00
|
| Other Properties |
|
18.07
|
| Non Current Prepaid Assets |
|
0.47
|
| Total Liabilities Net Minority Interest |
|
22.91
|
| Current Liabilities |
|
7.10
|
| Payables And Accrued Expenses |
|
4.88
|
| Payables |
|
2.65
|
| Accounts Payable |
|
2.57
|
| Other Payable |
|
—
|
| Current Accrued Expenses |
|
2.24
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.16
|
| Current Debt And Capital Lease Obligation |
|
1.06
|
| Current Capital Lease Obligation |
|
1.06
|
| Total Non Current Liabilities Net Minority Interest |
|
15.81
|
| Long Term Debt And Capital Lease Obligation |
|
12.21
|
| Long Term Debt |
|
5.61
|
| Long Term Capital Lease Obligation |
|
6.60
|
| Non Current Deferred Liabilities |
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
84.47
|
| Common Stock Equity |
|
84.47
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
69.67
|
| Ordinary Shares Number |
|
69.67
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
200.23
|
| Retained Earnings |
|
-115.76
|
| Total Equity Gross Minority Interest |
|
84.47
|
| Total Capitalization |
|
90.08
|
| Working Capital |
|
78.65
|
| Invested Capital |
|
90.08
|
| Total Debt |
|
13.28
|
| Capital Lease Obligations |
|
7.67
|
| Net Tangible Assets |
|
84.47
|
| Tangible Book Value |
|
84.47
|
| Derivative Product Liabilities |
|
3.60
|
| Dueto Related Parties Current |
|
0.08
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-26.68
-34.87%
|
-19.78
-10.16%
|
-17.96
+24.80%
|
-23.88
|
| Cash Flow From Continuing Operating Activities |
|
-26.68
-34.87%
|
-19.78
-10.16%
|
-17.96
+24.80%
|
-23.88
|
| Net Income From Continuing Operations |
|
-42.63
-34.26%
|
-31.75
-8.89%
|
-29.16
+13.64%
|
-33.76
|
| Depreciation Amortization Depletion |
|
1.23
+11.80%
|
1.10
+2.61%
|
1.07
+9.70%
|
0.98
|
| Depreciation |
|
1.23
+11.80%
|
1.10
+2.61%
|
1.07
+9.70%
|
0.98
|
| Depreciation And Amortization |
|
1.23
+11.80%
|
1.10
+2.61%
|
1.07
+9.70%
|
0.98
|
| Other Non Cash Items |
|
-0.24
-712.50%
|
0.04
-97.70%
|
1.74
+231.32%
|
-1.32
|
| Stock Based Compensation |
|
10.62
+7.07%
|
9.92
+25.11%
|
7.93
+17.46%
|
6.75
|
| Operating Gains Losses |
|
2.05
+891.89%
|
-0.26
+87.26%
|
-2.03
-153.67%
|
3.79
|
| Gain Loss On Investment Securities |
|
2.02
+878.38%
|
-0.26
+87.26%
|
-2.03
-153.67%
|
3.79
|
| Gain Loss On Sale Of PPE |
|
0.04
|
0.00
|
0.00
|
—
|
| Change In Working Capital |
|
2.29
+96.15%
|
1.17
-53.13%
|
2.49
+911.73%
|
-0.31
|
| Change In Prepaid Assets |
|
-0.07
+86.90%
|
-0.52
-358.21%
|
0.20
-84.49%
|
1.30
|
| Change In Payables And Accrued Expense |
|
1.47
-9.61%
|
1.62
-31.51%
|
2.37
+340.47%
|
-0.99
|
| Change In Payable |
|
1.47
-9.61%
|
1.62
-31.51%
|
2.37
+340.47%
|
-0.99
|
| Change In Account Payable |
|
0.34
-65.08%
|
0.96
-15.57%
|
1.14
+419.55%
|
0.22
|
| Change In Other Working Capital |
|
0.10
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
0.82
+3.55%
|
0.79
+8.23%
|
0.73
+36.26%
|
0.54
|
| Change In Other Current Liabilities |
|
-0.02
+96.83%
|
-0.73
+10.26%
|
-0.81
+29.77%
|
-1.15
|
| Investing Cash Flow |
|
-20.59
-199.13%
|
20.77
+11.17%
|
18.68
+120.77%
|
-89.94
|
| Cash Flow From Continuing Investing Activities |
|
-20.59
-199.13%
|
20.77
+11.17%
|
18.68
+120.77%
|
-89.94
|
| Net PPE Purchase And Sale |
|
-6.08
-171.45%
|
-2.24
+65.04%
|
-6.40
-608.08%
|
-0.90
|
| Purchase Of PPE |
|
-6.08
-171.45%
|
-2.24
+65.04%
|
-6.40
-608.08%
|
-0.90
|
| Capital Expenditure |
|
-6.08
-171.45%
|
-2.24
+65.04%
|
-6.40
-608.08%
|
-0.90
|
| Net Investment Purchase And Sale |
|
-14.51
-162.80%
|
23.11
-18.15%
|
28.23
+131.71%
|
-89.03
|
| Purchase Of Investment |
|
-70.49
+43.64%
|
-125.08
+23.56%
|
-163.63
-35.08%
|
-121.14
|
| Sale Of Investment |
|
55.98
-62.23%
|
148.19
-22.76%
|
191.86
+497.61%
|
32.10
|
| Net Other Investing Changes |
|
—
|
-0.10
+96.73%
|
-3.15
|
—
|
| Financing Cash Flow |
|
45.77
+182972.00%
|
0.03
-99.53%
|
5.30
-94.53%
|
96.91
|
| Cash Flow From Continuing Financing Activities |
|
45.77
+182972.00%
|
0.03
-99.53%
|
5.30
-94.53%
|
96.91
|
| Net Issuance Payments Of Debt |
|
0.00
|
0.00
-100.00%
|
5.25
|
0.00
|
| Issuance Of Debt |
|
5.15
|
0.00
-100.00%
|
5.25
|
0.00
|
| Repayment Of Debt |
|
-5.15
|
0.00
|
0.00
|
—
|
| Long Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
5.25
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
5.25
|
0.00
|
| Short Term Debt Issuance |
|
5.15
|
0.00
|
0.00
|
—
|
| Short Term Debt Payments |
|
-5.15
|
0.00
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
0.00
|
0.00
|
0.00
|
—
|
| Net Common Stock Issuance |
|
45.50
|
0.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.27
+988.00%
|
0.03
-48.98%
|
0.05
-98.54%
|
3.36
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
93.54
|
| Changes In Cash |
|
-1.50
-248.61%
|
1.01
-83.23%
|
6.02
+135.61%
|
-16.91
|
| Effect Of Exchange Rate Changes |
|
-0.02
-136.84%
|
0.06
+214.00%
|
-0.05
+80.62%
|
-0.26
|
| Beginning Cash Position |
|
13.72
+8.43%
|
12.66
+89.31%
|
6.69
-71.97%
|
23.85
|
| End Cash Position |
|
12.20
-11.09%
|
13.72
+8.43%
|
12.66
+89.31%
|
6.69
|
| Free Cash Flow |
|
-32.76
-48.75%
|
-22.02
+9.60%
|
-24.36
+1.71%
|
-24.78
|
| Interest Paid Supplemental Data |
|
0.38
+18.69%
|
0.32
+517.31%
|
0.05
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
-20.00%
|
0.01
-68.75%
|
0.02
+100.00%
|
0.01
|
| Common Stock Issuance |
|
45.50
|
0.00
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
45.50
|
0.00
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|